B+L and Clearside Launch Xipere
Bausch + Lomb and Clearside Biomedical announced the U.S. commercial launch of Xipere (triamcinolone acetonide injectable suspension), the first and only therapy approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis. Read more.
Icare USA Introduces iCare Home2
Icare USA announced FDA 510(k) clearance for its next-generation self-tonometer, the iCare Home2. The compay says the tonometer is designed for additional ease of use in measuring patients’ real-world intraocular pressure outside of normal clinic hours. A smart light guide and interactive display screen means most patients can utilize the iCare Home2 on their own, the device’s maker adds. iCare Home2’s new design enables IOP measurements to be taken while the patient is supine, reclined or sitting, iCare says. Learn more.
New Dry-eye Treatment Approved
Olympic Ophthalmics announced that the FDA has granted 510(K) approval for the company’s second-generation iTEAR100 device, a prescription neuromodulation therapy to acutely increase tear production in adult patients over a 30-day period. Read more.
Surgeons Implant First U.S. AccuraSee IOPCL
The first AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration was recently implanted as part of the company’s IDE study. The lens implant is placed on top of an existing posterior chamber intraocular lens implant in patients who have had previous cataract surgery, to help magnify images using areas of the retina not affected by macular degeneration. Read more.
STAAR Announces FDA Nod of EVO Visian ICL Lens
STAAR Surgical Company announced the FDA granted approval of the EVO/EVO+ Visian Implantable Collamer Lens for the correction of myopia and myopia with astigmatism. The lens has a central artificial hole that was added to improve aqueous humor circulation in the eye. This eliminates the need for a preoperative peripheral laser iridotomy or intraoperative peripheral iridectomy, which the company says simplifies the surgical procedure and significantly reduces the complications associated with iridotomy. Read more.
Prevent Blindness Declares April as Women’s Eye Health and Safety Awareness Month
Prevent Blindness declared April as Women’s Eye Health and Safety Awareness Month. A recent report, “The Lancet Global Health Commission on Global Eye Health: Vision Beyond 2020,” found a gender imbalance in which women are at higher risk of vision impairment and blindness than men can be attributed to demographic and social factors. Read more.
Luneau Launches as “Visionix”
Luneau Technology Group announced it will take on “Visionix” as its official global name beginning March 31. “Optovue” will transition to a product brand for Visionix’s OCT and OCTA line.